Note 6. Current assets - trade and other receivables Consolidated 2025 2024 $ $ GST receivable 95,430 35,419 R&D rebate receivable 2,806,583 2,323,371 Consulting fee receivable 45,000 45,000 2,947,013 2,403,790 Note 7. Non-current assets - financial assets at fair value through profit and loss Consolidated 2025 2024 $ $ Investment in Nyrada Inc.- ordinary shares - 1,969,022 Investment in Nyrada Inc.- performance shares - 40,802 - 2,009,824 ^ Refer to note 15 for further information on fair value measurement. The 12,000,600 Nyrada performance shares expired on 25 November 2024 without the performance hurdles being achieved and consequently have nil value, with a loss of $40,802 recorded to the profit and loss on expiry. Refer to note 2 Critical accounting judgements, estimates and assumptions including valuation techniques applied for the group’s value of its investment in Nyrada shares reflecting its Level 1 and level 3 investments. During the year, the 33,373,245 Nyrada shares were sold, generating $2,477,186 in cash and a net gain on sale of $506,163 net of costs, with this amount recognised through profit and loss and resulting in a nil asset value at 30 June 2025. Note 8. Current liabilities - trade and other payables Consolidated 2025 2024 $ $ Trade and other payables 450,871 649,446 Accrued expenses 539,595 186,076 Bank credit cards 8,042 9,182 Other payables - 72,940 998,508 917,644 ^ Refer to note 14 for further information on financial instruments. Annual Report 2025 34
RkJQdWJsaXNoZXIy MjE2NDg3